<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400306</url>
  </required_header>
  <id_info>
    <org_study_id>M15-536</org_study_id>
    <nct_id>NCT03400306</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer</brief_title>
  <official_title>A Phase 1, Single-Dose, Open-Label, Randomized Cross-Over Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the bioavailability between the veliparib tablet formulation to the
      capsule formulation; and will assess the effect of food on veliparib bioavailability in
      participants with ovarian cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2018</start_date>
  <completion_date type="Anticipated">April 12, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to approximately 8 days after initial dose of study drug</time_frame>
    <description>Maximum observed plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Up to approximately 8 days after initial dose of study drug</time_frame>
    <description>Time to maximum observed plasma concentration (Tmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Phase Elimination Rate Constant (β or Beta)</measure>
    <time_frame>Up to approximately 8 days after initial dose of study drug</time_frame>
    <description>Apparent terminal phase elimination rate constant (β or Beta).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-life (t1/2)</measure>
    <time_frame>Up to approximately 8 days after initial dose of study drug</time_frame>
    <description>Terminal phase elimination half-life (t1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt)</measure>
    <time_frame>Up to approximately 8 days after initial dose of study drug</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time 0 to time of the last measurable concentration (AUCt).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to infinite time (AUC∞)</measure>
    <time_frame>Up to approximately 8 days after initial dose of study drug</time_frame>
    <description>AUC from time 0 to infinite time (AUC∞)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Cancer - Ovarian</condition>
  <arm_group>
    <arm_group_label>Part 1, Bioequivalence Sequence Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: four 100 mg capsules under fasting conditions, followed by one 400-mg tablet under fasting conditions, then one 400 mg tablet under non-fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Veliparib as monotherapy or in combination with carboplatin and paclitaxel, per investigators' discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Bioequivalence Sequence Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: one 400-mg tablet under fasting conditions, followed by four 100 mg capsules under fasting conditions, then one 400 mg tablet under non-fasting conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib, capsule</intervention_name>
    <description>capsule; 50 mg or 100 mg</description>
    <arm_group_label>Part 1, Bioequivalence Sequence Group 1</arm_group_label>
    <arm_group_label>Part 1, Bioequivalence Sequence Group 2</arm_group_label>
    <arm_group_label>Part 2, Extension</arm_group_label>
    <other_name>ABT-888</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib, tablet</intervention_name>
    <description>tablet; 400 mg</description>
    <arm_group_label>Part 1, Bioequivalence Sequence Group 1</arm_group_label>
    <arm_group_label>Part 1, Bioequivalence Sequence Group 2</arm_group_label>
    <other_name>ABT-888</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Part 2, Extension</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Part 2, Extension</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

          -  Laboratory values meeting protocol-specified criteria, including hematologic, kidney
             and liver function.

          -  Life expectancy of 12 weeks or greater.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

          -  Able to swallow and retain oral medication.

          -  Discontinued anti-cancer therapy and biological agent for antineoplastic intent 28
             days prior to the first dose of study drug, not have undergone major surgery 28 days
             prior to the first dose of study drug; and have recovered to Grade 0 - 2 for any
             clinical significant adverse event effect(s)/toxicity(s) from previous therapy.

          -  Non-childbearing potential.

        Exclusion Criteria:

          -  History or active medical condition(s) affecting absorption or motility or any
             surgical procedure that might interfere with gastrointestinal motility, pH or
             absorption.

          -  Evidence of refractory ascites.

          -  Has clinically relevant or significant electrocardiogram abnormalities.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer Ovarian cancer Bioavailability Pharmacokinetics Bioequivalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Veliparib</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

